Success Metrics

Clinical Success Rate

66.7%

Based on 4 completed trials

Completion Rate

67%(4/6)

Active Trials

2(25%)

Results Posted

125%(5 trials)

Terminated

2(25%)

Phase Distribution

Ph phase_4

13%

Ph not_applicable

13%

Ph phase_2

50%

Ph phase_3

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution8 total trials

Phase 2Efficacy & side effects

4(50.0%)

Phase 3Large-scale testing

2(25.0%)

Phase 4Post-market surveillance

1(12.5%)

N/ANon-phased studies

1(12.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(4)

Terminated(2)

Detailed Status

Completed4

Recruiting2

Terminated2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

66.7%

Most Advanced

Phase 4

Trials by Phase

Phase 24 (50.0%)

Phase 32 (25.0%)

Phase 41 (12.5%)

N/A1 (12.5%)

Trials by Status

recruiting225%

terminated225%

completed450%

Recent Activity

2 active trials

Showing 5 of 8

recruitingphase_3

Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

NCT06513962

completednot_applicable

High-Dose Brachytherapy in Treating Patients With Prostate Cancer

NCT02346253

completedphase_3

A Study to Assess the Efficacy and Safety of the Triptorelin 6-month Formulation in Paediatric Participants With Central Precocious Puberty.

NCT05029622

recruitingphase_2

Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP

NCT03899077

completedphase_2

Triptorelin for Ovary Protection in Childhood Onset Lupus

NCT00124514

View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials

NCT06513962Phase 3

Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

Recruiting

NCT02346253Not Applicable

High-Dose Brachytherapy in Treating Patients With Prostate Cancer

Completed

NCT05029622Phase 3

A Study to Assess the Efficacy and Safety of the Triptorelin 6-month Formulation in Paediatric Participants With Central Precocious Puberty.

Completed

NCT03899077Phase 2

Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP

Recruiting

NCT00124514Phase 2

Triptorelin for Ovary Protection in Childhood Onset Lupus

Completed

NCT02168062Phase 2

Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer

Terminated

NCT00194792Phase 2

Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer

Terminated

NCT01161563Phase 4

Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration

Completed

All 8 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 8